Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 1

Conditions

Colorectal Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Fallopian Tube Neoplasms 2Uterine Cervical Neoplasms 1Sarcoma, Alveolar Soft Part 1Rectal Neoplasms 1Rectal Diseases 1Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Colonic Neoplasms 1Colonic Diseases 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Brenner Tumor 1

Interventions

pembrolizumab 25Cisplatin 9Paclitaxel 6Fluorouracil 5Carboplatin 4Saline Solution 3Capecitabine 3Bevacizumab 3Oxaliplatin 2Gemcitabine 2Docetaxel 2Cetuximab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2lenvatinib 1Trastuzumab 1S 1 (combination) 1Irinotecan 1IFL protocol 1Glucose 1Doxorubicin 1Brentuximab Vedotin 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Parkinson Disease 4, Autosomal Dominant Lewy Body × Bevacizumab × Clear all
NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

Merck Sharp & Dohme LLC

Phase 3 Completed
617 enrolled 29 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT02563002 2024-10-03

KEYNOTE-177

Merck Sharp & Dohme LLC

Phase 3 Completed
307 enrolled 16 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡